Eutilex, a Korean biotech company, received 21 billion won ($18.9 million) in Series A financing to advance the company's mid-term trial of anti-cancer drugs. DS Asset Management, Kolon Investment, GN Tech Venture and SNU Bio Angel all made a splash, bringing the total capital of the company that was just established last year to 30.5 billion won ($27.7 million). The financing will be mainly used to promote the research and development of immuno-oncology, establish new GMP facilities in Seoul to improve research and development capabilities, and promote the leading 4-1BB CTL into Phase II research. The biotech startup said the deal was one of South Korea's "one of the largest private financing projects in the life sciences" this year. The company's autologous T-cell therapy is performed by injecting the patient's own anti-tumor CD8 + T cells in vitro and then re-injecting them into the patient. In this way, modified T cells can detect and kill tumor cells. Due to some safety issues in similar cell research projects this year, Juno Pharmaceuticals used CAR-T therapy to treat some patients with hematological tumors, and this research topic is chilling. But Eutilex says the treatment it uses "resistably performs well because it uses a naturally selected peripheral T cell receptor library." APIs And Parmaceutical Intermediates Apis And Parmaceutical Intermediates,Pitavastatin Calcium,Tropisetron Hydrochloride,Lipoic Acid Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com